¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"nicotinic cholinergic receptor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
¿µ¹® receptor ÇÑ±Û ¼ö¿ëü
¼³¸í   
  ¼¼Æ÷Áú³» ¶Ç´Â ¼¼Æ÷Ç¥¸é¿¡ Á¸ÀçÇϴ ºÐÀÚ±¸Á¶·Î¼­ Æ¯À̹°Áú°ú ¼±ÅÃÀûÀ¸·Î °áÇÕÇϸ砰áÇÕ¿¡ ÀÇÇØ Æ¯ÀÌÇÑ »ý¸®Àû ÀÛ¿ëÀ» ³ªÅ¸³½´Ù. ÆéƼµåÈ£¸£¸ó, ½Å°æÀü´Þ¹°Áú, Ç׿ø, º¸Ã¼, ¸é¿ª±Û·ÎºÒ¸°¿¡ ´ëÇÑ ¼¼Æ÷Ç¥¸é ¼ö¿ëü¿Í ½ºÅ×·ÎÀ̵忡 ´ëÇÑ ¼¼Æ÷Áú³» ¼ö¿ëü°¡ ÀÖ´Ù.
¿µ¹® cholinergic ÇÑ±Û Äݸ°(ÀÛµ¿)¼º
¼³¸í   
  1.½Å°æ¼¼Æ÷°¡ ´Ù¸¥ ½Å°æ¼¼Æ÷·Î Á¤º¸¸¦ Àü´ÞÇÒ °æ¿ì¿¡´Â ´ëºÎºÐ È­Çй°ÁúÀ» ºÐºñÇÏ¿© ±×°ÍÀ» ¸Å°³·Î ÇÏ¿© ´Ù¸¥ ½Å°æ¿¡ Á¤º¸¸¦ Àü´ÞÇÑ´Ù. ÀÌ·± ¹°ÁúÀ» ½Å°æÀü´Þ¹°Áú¶ó°í ÇÑ´Ù. Äݸ°¼ºÀ̶õ ½Å°æÀü´Þ¹°Áú·Î acetylcholineÀ» »ç¿ëÇϴ ½Å°æÀ» À̸£´Â ¸»ÀÌ´Ù. Áα³°¨½Å°æÀ» À̸£´Â ¸»·Î ¾²ÀδÙ.
  
  2. Acetylcholine°ú À¯»çÇÑ ¾à¸®Àû ÀÛ¿ëÀ» ÇÏ´Â.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • nicotinic receptor
    ´ÏÄÚÆ¾¼ö¿ëü
  • cholinergic receptor
    Äݸ°¼ö¿ëü
  • nicotinic
    ´ÏÄÚÆ¾ÀÛ¿ë-, ´ÏÄÚÆ¾-
  • nicotinic acid
    ´ÏÄÚÆ¾»ê
  • cholinergic
    1. Äݸ°¼º- 2. Äݸ°¼ºÁ¦Á¦
  • cholinergic agent
    Äݸ°¼º¾à¹°
  • cholinergic agonist
    Äݸ°¼ºÀÛ¿ëÁ¦
  • cholinergic blocking agent
    Äݸ°Â÷´ÜÁ¦
  • cholinergic crisis
    Äݸ°ÀÛµ¿¼ºÀ§±â
  • cholinergic fiber
    Äݸ°¼¶À¯
  • cholinergic nerve
    Äݸ°½Å°æ
  • cholinergic neuron
    Äݸ°½Å°æ¼¼Æ÷
  • cholinergic pruritus
    Äݸ°°¡·Á¿ò(Áõ)
  • antigen binding receptor
    Ç׿ø°áÇÕ¼ö¿ëü
  • antigen receptor
    Ç׿ø¼ö¿ëü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cholinergic
    Äݸ°¼ºÁ¦Á¦, Äݸ°¼º-
  • receptor blocker
    ¼ö¿ëüÂ÷´ÜÁ¦
  • receptor binding
    ¼ö¿ëü°áÇÕ
  • receptor
    ¼ö¿ëü, ¼ö¿ë±â
  • antigen receptor
    Ç׿ø¼ö¿ëü
  • opiate receptor
    ¾ÆÆí¼ö¿ëü
  • sensory receptor
    °¨°¢¼ö¿ëü
  • receptor site
    ¼ö¿ëüºÎÀ§
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • nicotinic receptor
    ´ÏÄÚÆ¾¼ö¿ëü
  • cholinergic receptor
    Äݸ°¼ö¿ëü
  • nicotinic acid
    ´ÏÄÚÆ¾»ê
  • cholinergic agent
    Äݸ°¼º¾à¹°
  • cholinergic agonist
    Äݸ°¼ºÃËÁøÁ¦
  • cholinergic blocking agent
    Äݸ°Â÷´ÜÁ¦
  • cholinergic
    Äݸ°¼ºÁ¦Á¦, Äݸ°¼º-
  • cholinergic crisis
    Äݸ°À§±â
  • cholinergic fiber
    Äݸ°¼¶À¯
  • cholinergic nerve
    Äݸ°¼º½Å°æ
  • cholinergic neuron
    Äݸ°¼º½Å°æ¼¼Æ÷
  • cholinergic pruritus
    Äݸ°¼º°¡·Á¿òÁõ
  • adrenergic receptor
    ¾Æµå·¹³¯¸°¼ö¿ëü
  • androgen receptor
    ¾Èµå·Î°Õ¼ö¿ëü
  • antigen receptor
    Ç׿ø¼ö¿ëü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Cholinergic urticaria
    Äݸ°¼º ´ã¸¶Áø
  • A1 receptor
    A1 ¼ö¿ëü(¼ö¿ë±â, °¨¼ö±â)
  • A2 receptor
    A2 ¼ö¿ëü(¼ö¿ë±â, °¨¼ö±â)
  • CR1 => complement receptor 1
    º¸Ã¼¼ö¿ëü 1
  • CR2 => complement receptor 2
    º¸Ã¼¼ö¿ëü 2
  • CR3 => complement receptor 3
    º¸Ã¼¼ö¿ëü 3
  • CR4 => complement receptor 4
    º¸Ã¼¼ö¿ëü 4
  • Gustatory receptor
    ¹Ì°¢¼ö¿ëü(Ú«ÊÆâ¥é»ô÷)
  • H2 receptor antagonist
    H2 ¼ö¿ëü ±æÇ×Á¦µé
  • Ig receptor
    ¸é¿ª±Û·ÎºÒ¸° ¼ö¿ëü
  • Internalization, receptor
    ³»È­(Ò®ü§), ¼ö¿ëü(áôé»ô÷)
  • Kainate amino acid receptor
    Ä«À̳×ÀÌÆ® ¾Æ¹Ì³ë»ê ¼ö¿ëü(áôé»ô÷)
  • Kinesthetic receptor
    ¿îµ¿(ê¡ÔÑ)(°¨(Êï))°¢¼ö¿ëü(ÊÆáôé»ô÷)
  • NMDA receptor
    ¿£¾Úµð¿¡ÀÌ ¼ö¿ëü
  • T cell receptor
    T¼¼Æ÷[Ç׿ø]¼ö¿ëü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • nicotinic receptor
    ´ÏÄÚÆ¾ ¼ö¿ëü
  • cholinergic receptor
    Äݸ°(ÀÛµ¿)¼º ¼ö¿ëü(¼ö¿ë±â, °¨¼ö±â)
  • nicotinic
    ´ÏÄÚÆ¾ÀÛ¿ëÀÇ
  • nicotinic
    ´ÏÄÚÆ¾ÀÇ, ´ÏÄÚÆ¾(ÀÛµ¿)¼ºÀÇ.
  • nicotinic acid
    ´ÏÄÚÆ¾»ê(~ß«).
  • nicotinic acid
    ´ÏÄÚÆ¾»ê
  • nicotinic action
    ´ÏÄÚÆ¾ÀÛ¿ë(~íÂéÄ).
  • nicotinic action
    ´ÏÄÚÆ¾(¼º)ÀÛ¿ë(~íÂéÄ).
  • nicotinic effect
    ´ÏÄÚÆ¾ÀÛ¿ë, ´ÏÄÚÆ¾È¿°ú.
  • nicotinic effect
    ´ÏÄÚÆ¾(¼º)È¿°ú.
  • cholinergic
    (¾Æ¼¼Æ¿)Äݸ°¼º.
  • cholinergic agent
    Äݸ°¼º ¾à¹°(å·Úª)
  • cholinergic agonist
    Äݸ°¼º ÃËÁøÁ¦
  • cholinergic blocking agent
    Äݸ°¼ºÂ÷´ÜÁ¦
  • cholinergic blocking agent
    Ç×Äݸ°¼º¾à(ù÷¡­å·), Äݸ°¼º Â÷´Ü<ºÀ¼â>Á¦.
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Receptor
    ¼ö¿ë±â
    [¿¾ ¿ë¾î] ¼ö¿ë±â
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • nicotinic receptor
    ´ÏÄÚÆ¾¼ö¿ëü(â¥é»ô÷)
  • cholinergic agonist
    Äݸ°ÀÛµ¿Á¦(íÂÔÑð¥)
  • cholinergic antagonist
    Äݸ°±æÇ×Á¦(ÑÏù÷ð¥)
  • nicotinic acid
    ´ÏÄÚÆ¾»ê(ß«)
  • nicotinic acid amide
    ´ÏÄÚÆ¾»ê(ß«) ¾Æ¸¶À̵å
  • nicotinic synapse
    "´ÏÄÚÆ¾½Ã³³½º, ´ÏÄÚÆ¾¿¬Á¢ºÎ(Ö§ïÈÝ»)"
  • adrenergic receptor
    ¾Æµå·¹³¯¸°ÀÛµ¿(íÂÔÑ) ¼ö¿ëü(áôé»ô÷)
  • alpha adrenergic receptor
    ¾ËÆÄ¾Æµå·¹³ª¸°ÀÛµ¿¼º(íÂÔÑàõ) ¼ö¿ëü(áôé»ô÷)
  • alpha receptor
    ¾ËÆÄ¼ö¿ëü(áôé»ô÷)
  • beta adrenergic receptor
    º£Å¸ ¾Æµå·¹³¯¸° ¼ö¿ëü(áôé»ô÷)
  • beta receptor
    º£Å¸ ¼ö¿ëü(áôé»ô÷)
  • cyclic AMP receptor protein
    °í¸®AMP ¼ö¿ëü ´Ü¹éÁú(áôé»ô÷Ó±ÛÜòõ)
  • dopamine adrenergic receptor
    "µµÆÄ¹Î ¾Æµå·¹³¯¸°ÀÛµ¿¼º(íÂÔÑàõ) ¼ö¿ëü(áôé»ô÷), (ÔÒ) adrenergic receptor"
  • Ehrlich's receptor theory
    ¿¡¸¦¸®È÷ ¼ö¿ëüÀÌ·Ð(áôé»ô÷×âÖå)
  • Fc receptor
    Fc ¼ö¿ëü(áôé»ô÷)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cholinergic
    Äݸ°¼º
  • receptor
    ¼ö¿ë±â, ¼ö¿ëü, °¨¼öü
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
nAChR nicotinic acetylcholine receptor
CAN'T LEAP cyclosporine, alcohol, nicotinic acid, thiazides, lasix, ethambutanol, aspirin, pyrazinamide [s...
NA Avogadro constant or number; nalidixic acid; Narcotics Anonymous; network administrator; neuraminida...
NAA N-acetyl aspartate; naphthaleneacetic acid; neutral amino acid; neutron activation analysis; neutrop...
NAD neutrophil actin dysfunction; new antigenic determinant; nicotinamide adenine dinucleotide; nicotini...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
nAChR Nicotinic ACh receptor
nAChR Nicotinic acetylcholine receptor
nAcChoR nicotinic acetylcholine receptor
CBF Cholinergic basal forebrain
HCNP Hippocampal cholinergic neurostimulating peptide
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • nicotinic
    ´ÏÄÚÆ¾¼º
    ´ÏÄÚÆ¾ ÀÛ¿ëÀÇ. ÀÚÀ²½Å°æÀý ¹× ½Å°æ ±ÙÀ° Á¢ÇÕ¿¡¼­ ½Å°æ Ãæµ¿À» ÀÚ±ØÇÏ°í ´ë·®ÀÏ ¶§´Â À̰ÍÀ» ¾ïÁ¦ÇÏ´Â ´ÏÄÚÆ¾°ú ±× ¿ÜÀÇ ¾à¹°ÀÇ È¿°ú¸¦ ³ªÅ¸³»´Â.
  • nicotinic action
    ´ÏÄÚÆ¾ ÀÛ¿ë
  • nicotinic leukokeratosis
    ´ÏÄÚÆ¾¼º ¹é¹Ý °¢È­Áõ
  • nicotinic stomatitis
    ´ÏÄÚÆ¾¼º ±¸³»¿°
  • cholinergic
    Äݸ°¼º, Äݸ° ÀÛµ¿¼º
    ¾à¸®ÇÐÀû ÀÛ¿ë¿¡¼­ ¾Æ¼¼Æ¿Äݸ°°ú °°Àº ÀÛ¿ëÀ» ÇÏ´Â. ¾Æ¼¼Æ¿Äݸ°À» ºÐºñÇϰųª ¾Æ¼¼Æ¿Äݸ°¿¡ ÀÇÇØ ÀÚ±ØÀ» ¹Þ´Â.
  • cholinergic blocking agent
    Ç×Äݸ°¾à, Äݸ°¼º Â÷´ÜÁ¦
  • cholinergic drug
    Äݸ° ÀÛ¿ë ¾à
  • cholinergic internuncial neuron
    Äݸ° °³Àç ´º¿ì·Ð
  • cholinergic postganglionic fiber
    Äݸ°¼º ÀýÈÄ ¼¶À¯
  • cholinergic transmission
    Äݸ°¼º Àü´Þ
  • 5-HT1 receptor antagonist
    5-HT1 ¼ö¿ë±â ±æÇ×Á¦
    ÀÏÂïÀÌ 5-hydroxytry
  • A1 receptor
    A1 ¼ö¿ëü, A1 ¼ö¿ë±â, A1 °¨¼ö±â
  • acetylcholine receptor
    ¾Æ¼¼Æ¿Äݸ° ¼ö¿ëü
  • alpha-adrenergic receptor
    ¾ËÆÄ-¾Æµå·¹³¯¸° ¼ö¿ëü
  • antigen receptor
    Ç׿ø ¼ö¿ëü
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
nicotinic cholinergic receptor A class of receptors responsive to acetylcholine that also are activated by nicotine; ganglionic (including the adrenal medulla) and neuromuscular receptors. Two classes exist: nicotinic-neuronal and nicotinic-muscular.
(05 Mar 2000)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
nicotinic acetylcholine receptor Integral membrane protein of the postsynaptic membrane to which acetylcholine binds. The receptor contains an integral ion channel, as a result of binding of acetylcholine, ion channels in the subsynaptic membrane are opened. at the neuromuscular junction, the nicotinic acetylcholine receptor initiates muscle contraction. Currently the best characterised ion channel protein: made of a hetero pentamer of related subunits, although a homo pentamer is functional in insects. Structural studies show that the acetylcholine binding site and the ionic channel are part of the same macromolecular unit. The nAChR mediates rapid transduction events (1ms) whereas receptors activating G-protein coupled channels operate on slower time scales (millisecond to second range).
(18 Nov 1997)
receptors, nicotinic One of the two major classes of cholinergic receptors. Nicotinic receptors were originally distinguished by their preference for nicotine over muscarine. They are generally divided into muscle-type and neuronal-type (previously ganglionic) based on pharmacology, molecular biology, and biophysical properties of the channels.
(12 Dec 1998)
nicotinic <chemistry> Pertaining to, or derived from, nicotine; nicotic; used specifically to designate an acid related to pyridine, obtained by the oxidation of nicotine, and called nicotinic acid.
Source: Websters Dictionary
(01 Mar 1998)
nicotinic acid A precursor of NAD, that is a product of the oxidation of nicotine.
(18 Nov 1997)
nicotinic acid amide <biochemistry> Member of the water soluble B vitamin group, used in the production of fatty acids, steroids and cholesterol, deficiency is known as pellagra. Has cholesterol-lowering and vasodilating properties.
(27 Sep 1997)
nicotinic acid maculopathy Maculopathy observed in persons taking 3000 mg or more of nicotinic acid daily; normal vision returns after this medication is discontinued.
(05 Mar 2000)
nicotinic acids 2-, 3-, or 4-pyridinecarboxylic acids. Pyridine derivatives substituted with a carboxy group at the 2-, 3-, or 4-position. The 3-carboxy derivative (niacin) is active as a vitamin.
(12 Dec 1998)
nicotinic agonists Drugs that bind to and activate nicotinic cholinergic receptors (receptors, nicotinic). Nicotinic agonists act at postganglionic nicotinic receptors, at neuroeffector junctions in the peripheral nervous system, and at nicotinic receptors in the central nervous system. Agents that function as neuromuscular depolarising blocking agents are included here because they activate nicotinic receptors, although they are used clinically to block nicotinic transmission.
(12 Dec 1998)
nicotinic alcohol <chemical> 3-pyridinemethanol. A direct-acting peripheral vasodilator that causes flushing and may decrease blood pressure. It is used in vasospasm and threatened gangrene.
Pharmacological action: vasodilator agents.
Chemical name: 3-Pyridinemethanol
(12 Dec 1998)
nicotinic antagonists Drugs that bind to nicotinic cholinergic receptors (receptors, nicotinic) and block the actions of acetylcholine or cholinergic agonists. Nicotinic antagonists block synaptic transmission at autonomic ganglia, the skeletal neuromuscular junction, and at central nervous system nicotinic synapses.
(12 Dec 1998)
nicotinic receptors A class of cholinergic receptors on skeletal muscle cells that are linked to ion channels in the cell membrane.
(05 Mar 2000)
receptors, cholinergic Cell surface proteins that bind acetylcholine with high affinity and trigger intracellular changes influencing the behaviour of cells. Cholinergic receptors are divided into two major classes, muscarinic and nicotinic, based originally on their affinity for nicotine and muscarine. Each group is further subdivided based on pharmacology, location, mode of action, and/or molecular biology.
(12 Dec 1998)
cholinergic <pharmacology> Resembling acetylcholine in pharmacological action, stimulated by or releasing acetylcholine or a related compound.
(15 Jan 1998)
cholinergic agent An agent that mimics the action of the parasympathetic nervous system (e.g., methacholine).
(05 Mar 2000)
cholinergic agents Any drug used for its actions on cholinergic systems. Included here are agonists and antagonists, drugs that affect the life cycle of acetylcholine, and drugs that affect the survival of cholinergic neurons. The term cholinergic agents is sometimes still used in the narrower sense of muscarinic agonist, although most modern texts discourage that usage.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • receptor
    ¼ö¿ë±â;°¨°¢±â°ü;¼ö¿ëü
  • receptor site
    ¼¼Æ÷³» ¼ö¿ë ¿µ¿ª
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á